- Home
- DOW vs SNN Comparison
DOW vs SNN Comparison
Compare DOW & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOW
- SNN
- Stock Information
- Founded
- DOW 1897
- SNN 1856
- Country
- DOW United States
- SNN United Kingdom
- Employees
- DOW N/A
- SNN N/A
- Industry
- DOW Major Chemicals
- SNN Industrial Specialties
- Sector
- DOW Industrials
- SNN Health Care
- Exchange
- DOW Nasdaq
- SNN Nasdaq
- Market Cap
- DOW 16.3B
- SNN 13.2B
- IPO Year
- DOW N/A
- SNN 1999
- Fundamental
- Price
- DOW $22.05
- SNN $35.75
- Analyst Decision
- DOW Hold
- SNN Hold
- Analyst Count
- DOW 15
- SNN 3
- Target Price
- DOW $28.13
- SNN $31.50
- AVG Volume (30 Days)
- DOW 13.5M
- SNN 655.1K
- Earning Date
- DOW 10-23-2025
- SNN 10-30-2025
- Dividend Yield
- DOW 6.34%
- SNN 2.05%
- EPS Growth
- DOW N/A
- SNN 59.91
- EPS
- DOW N/A
- SNN 0.56
- Revenue
- DOW $41,819,000,000.00
- SNN $5,944,000,000.00
- Revenue This Year
- DOW N/A
- SNN $7.75
- Revenue Next Year
- DOW $2.95
- SNN $5.37
- P/E Ratio
- DOW N/A
- SNN $64.05
- Revenue Growth
- DOW N/A
- SNN 5.35
- 52 Week Low
- DOW $20.40
- SNN $23.69
- 52 Week High
- DOW $54.17
- SNN $38.79
- Technical
- Relative Strength Index (RSI)
- DOW 36.20
- SNN 43.63
- Support Level
- DOW $22.25
- SNN $35.66
- Resistance Level
- DOW $24.04
- SNN $36.48
- Average True Range (ATR)
- DOW 0.71
- SNN 0.43
- MACD
- DOW -0.07
- SNN -0.12
- Stochastic Oscillator
- DOW 4.04
- SNN 39.20
About DOW Dow Inc.
Dow Chemical is a diversified global chemicals producer, formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a leading producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in both consumer and industrial end markets.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.